Evidence map›Paper›PMID 31043706›Full record

ArticleOncogene2019

Non-canonical HIF-1 stabilization contributes to intestinal tumorigenesis.

Nadine Rohwer, Sandra Jumpertz, Merve Erdem, Antje Egners, Klaudia T Warzecha, Athanassios Fragoulis, Anja A Kühl, Rafael Kramann, Sabine Neuss, Ines Rudolph and 16 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Roxadustat: Do we know all the answers?Biomolecules & biomedicine · 2023
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Dihydroartemisinin ameliorates chronic nonbacterial prostatitis and epithelial cellular inflammation by blocking the E2F7/HIF1α pathway.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Wnt Signaling in the Tumor Microenvironment.Advances in experimental medicine and biology · 2021
    Article
  20. Epigenetic crosstalk between hypoxia and tumor driven by HIF regulation.Journal of experimental & clinical cancer research : CR · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 8 institutions in 4 countries.

Nadine RohwerHepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Sandra JumpertzMolecular Tumor Biology, Department of General Visceral and Transplantation Surgery, RWTH University Hospital, Pauwelsstraße 30, 52074, Aachen, Germany.
Merve ErdemMolecular Tumor Biology, Department of General Visceral and Transplantation Surgery, RWTH University Hospital, Pauwelsstraße 30, 52074, Aachen, Germany.
Antje EgnersMolecular Tumor Biology, Department of General Visceral and Transplantation Surgery, RWTH University Hospital, Pauwelsstraße 30, 52074, Aachen, Germany.
Klaudia T WarzechaMedicine III, RWTH University Hospital, Pauwelsstraße 30, 52074, Aachen, Germany.
Athanassios FragoulisMolecular Tumor Biology, Department of General Visceral and Transplantation Surgery, RWTH University Hospital, Pauwelsstraße 30, 52074, Aachen, Germany.
Anja A KühlResearch Center Immunosciences, Charité Universitätsmedizin Berlin, Hindenburgdamm 30, 12200, Berlin, Germany.
Rafael KramannMedicine II, RWTH University Hospital, Pauwelsstraße 30, 52074, Aachen, Germany.
Sabine NeussPathology, RWTH University Hospital, Pauwelsstraße 30, 52074, Aachen, Germany.
Ines RudolphHepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Tobias EndermannExperimental Endocrinology, Charité Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Christin ZasadaMax-Delbrück-Centrum, Robert-Rössle-Straße 10, 13125, Berlin, Germany.
Ivayla ApostolovaNuclear Medicine, Charité Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Marco GerlingBiosciences and Nutrition, Karolinska Institutet, Alfred Nobels Allé 8, 17177, Stockholm, Sweden.
Stefan KempaMax-Delbrück-Centrum, Robert-Rössle-Straße 10, 13125, Berlin, Germany.
Russell HughesOncology and Metabolism, University of Sheffield Medical School, Sheffield, S10 2RX, UK.
Claire E LewisOncology and Metabolism, University of Sheffield Medical School, Sheffield, S10 2RX, UK.
Winfried BrennerNuclear Medicine, Charité Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Maciej B MalinowskiSurgery, Charité Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Martin StockmannSurgery, Charité Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Lutz SchomburgExperimental Endocrinology, Charité Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.ORCID http://orcid.org/0000-0001-9445-1555
William FallerCancer Research UK Beatson Institute, Glasgow, G61 1BD, UK.ORCID http://orcid.org/0000-0002-0738-2254
Owen J SansomCancer Research UK Beatson Institute, Glasgow, G61 1BD, UK.ORCID http://orcid.org/0000-0001-9540-3010
Frank TackeMedicine III, RWTH University Hospital, Pauwelsstraße 30, 52074, Aachen, Germany.
Markus MorkelInstitute for Pathology, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Thorsten CramerMolecular Tumor Biology, Department of General Visceral and Transplantation Surgery, RWTH University Hospital, Pauwelsstraße 30, 52074, Aachen, Germany. tcramer@ukaachen.de.ORCID http://orcid.org/0000-0002-6462-239X
Charité - Universitätsmedizin Berlin · DERWTH Aachen University · DEMax Delbrück Center · DEUniversity of Sheffield · GBCancer Research UK Scotland Institute · GBKarolinska Institutet · SEMaastricht University · NLThe Netherlands Cancer Institute · NL

Funding

Cancer Research UK 21139
6 · The paper itself

Abstract

The hypoxia-inducible transcription factor HIF-1 is appreciated as a promising target for cancer therapy. However, conditional deletion of HIF-1 and HIF-1 target genes in cells of the tumor microenvironment can result in accelerated tumor growth, calling for a detailed characterization of the cellular context to fully comprehend HIF-1's role in tumorigenesis. We dissected cell type-specific functions of HIF-1 for intestinal tumorigenesis by lineage-restricted deletion of the Hif1a locus. Intestinal epithelial cell-specific Hif1a loss reduced activation of Wnt/β-catenin, tumor-specific metabolism and inflammation, significantly inhibiting tumor growth. Deletion of Hif1a in myeloid cells reduced the expression of fibroblast-activating factors in tumor-associated macrophages resulting in decreased abundance of tumor-associated fibroblasts (TAF) and robustly reduced tumor formation. Interestingly, hypoxia was detectable only sparsely and without spatial association with HIF-1α, arguing for an importance of hypoxia-independent, i.e., non-canonical, HIF-1 stabilization for intestinal tumorigenesis that has not been previously appreciated. This adds a further layer of complexity to the regulation of HIF-1 and suggests that hypoxia and HIF-1α stabilization can be uncoupled in cancer. Collectively, our data show that HIF-1 is a pivotal pro-tumorigenic factor for intestinal tumor formation, controlling key oncogenic programs in both the epithelial tumor compartment and the tumor microenvironment.

Indexed as

AnimalsColorectal NeoplasmsFemaleHypoxia-Inducible Factor 1, alpha SubunitIntestinal MucosaMacrophagesMaleMiceMice, Inbred C57BLOncogenesProtein StabilityTumor MicroenvironmentHif1a protein, mouseHypoxia-Inducible Factor 1, alpha Subunit

Identifiers

PMID31043706
OpenAlexW2943407345

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.